See today's BioWorld Science
To read the full story, subscribe or sign in.
Gastrointestinal

Qu Biologics’ Qbeco SSI improves fatty liver disease in mouse model of obesity

Jan. 7, 2025
Qu Biologics Inc. has reported data showing that its Qbeco site specific immunomodulator (SSI) improved fatty liver disease.
BioWorld Science Endocrine/metabolic Gastrointestinal